New York City
9 articles with Kallyope
2/8/2019In this week's edition of Movers and Shakers, biopharma companies tap executives to serve in various leadership roles.
Kallyope Inc., a leading biotechnology company focused on identifying therapeutic opportunities involving the gut-brain axis, announced that it has appointed Brett Lauring, M.D., Ph.D.
Entry of Bill Gates and additional investment from existing syndicate raises Series B total to $87 million
Kallyope and Novo Nordisk Announce Collaboration to Discover Novel Therapeutics for Obesity and Diabetes
Kallyope Inc. and Novo Nordisk A/S announced that they have entered into a research collaboration and option agreement to discover novel peptide therapeutics to treat obesity and diabetes.
New York-based Kallyope and Danish company Novo Nordisk A/S signed a research collaboration and option deal to discover novel therapeutics to treat obesity and diabetes.
All existing backers including Lux Capital, The Column Group, and Polaris Partners joined by new investors Euclidean Capital and Two Sigma Ventures
New York-based Kallyope Inc. has secured an additional $66 million in Series B funding that it will use to continue its work harnessing the communicative pathways between the digestive tract and the brain to develop new therapies for various illnesses.